Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Voyager Therapeut (VYGR)

Voyager Therapeut (VYGR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Voyager Therapeut 75 HAYDEN AVENUE LEXINGTON MA 02421 USA

www.voyagertherapeutics.com P: 857-259-5340

Description:

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 486,229
Enterprise Value, $K 417,429
Shares Outstanding, K 54,388
Annual Sales, $ 250,010 K
Annual Net Income, $ 132,330 K
Last Quarter Sales, $ 90,060 K
Last Quarter Net Income, $ 56,400 K
EBIT, $ 122,000 K
EBITDA, $ 122,820 K
60-Month Beta 0.98
% of Insider Shareholders 4.70%
% of Institutional Shareholders 48.03%
Float, K 51,832
% Float 95.30%
Short Volume Ratio 0.73

Growth:

1-Year Return 9.18%
3-Year Return 96.05%
5-Year Return -59.64%
5-Year Revenue Growth 3,180.97%
5-Year Earnings Growth 208.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.25 on 02/28/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm 3.09
EPS Growth vs. Prev Qtr 311.86%
EPS Growth vs. Prev Year 304.92%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

VYGR Ratios

Ratio
Price/Earnings ttm 2.85
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 63.89%
Return-on-Assets % 40.79%
Profit Margin % 52.93%
Debt/Equity 0.00
Price/Sales 1.92
Price/Cash Flow 2.82
Price/Book 1.59
Book Value/Share 5.37
Interest Coverage 4.73
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar